VivoSeq
Ophthalmology

Glaucoma

120

Pipeline Programs↗

30

Active Trials↗

44

Companies Involved↗

Glaucoma is a highly competitive landscape with 120 programs across 44 companies. The most active players are ONL Therapeutics, Isarna Therapeutics GmbH, Merz Pharmaceuticals GmbH. 43 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

39/100

Mech. Concentration

16/100

Completion Rate

85/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

ONL Therapeutics

1 program

Phase 1I

Isarna Therapeutics GmbH

1 program

Phase 1M

Merz Pharmaceuticals GmbH

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1V

Vistakon Pharmaceuticals

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical24

Triamcinolone

Bassett Healthcare

Brimonidine Tartrate

AbbVie

Lisdexamfetamine Dimesylate

Takeda

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ketorolac

Javelin Pharmaceuticals

Phase 19

Infliximab

Organon and Co

Omeprazole

Dexcel Pharma Technologies Ltd.

Bosentan

Johnson & Johnson

Insulin

Merck & Co.

INS117548

Merck & Co.

Phase 222

Prednisolone Acetate

Novartis

Mitomycin

UroGen Pharma Ltd.

Metformin

EMD Serono

Mitomycin C

Gynecologic Oncology Group

NT-501

Neurotech Pharmaceuticals

Phase 322

Aflibercept

Regeneron

Bevacizumab

Bio-Thera Solutions

Sildenafil

Viatris Specialty LLC

Ranibizumab

Roche

Memantine

AbbVie

Approved43

Clonidine

Boehringer Ingelheim

Latanoprost

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Acetylcholine

Bausch Health Americas, Inc.

Brimonidine

Novartis

Bimatoprost

AbbVie

Analysis

Modality Breakdown

96%

Small molecule

172 of 180 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody42%Protein / enzyme21%Peptide1<1%Cell therapy1<1%

Small molecule leads; the ring shows all 180 classified programs, each share of the total. Modality classified for 99% of 183 pipeline programs.

Analysis

Trial Status

186

clinical trials

Completed98 · 53%
Unknown status41 · 22%
Recruiting16 · 9%
Terminated10 · 5%
Active, not recruiting8 · 4%
Withdrawn6 · 3%
Other7 · 4%

Clinical Trials

Trial Activity

186 trials

Metformin as a Neuroprotective Therapy for Glaucoma
Recruiting·CChristopher Kai Shun Leung·Phase 2·NCT05426044·125 enrolled
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Recruiting·UUniversity of California, Los Angeles·N/A·NCT04354545·75 enrolled
Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
Recruiting·UUniversity of Maryland, Baltimore·N/A·NCT06993597·60 enrolled
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
Recruiting·AAmydis Inc.·Phase 2·NCT06223048·50 enrolled
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
Recruiting·—·Phase 3·NCT05710198·1,000 enrolled
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
Recruiting·—·Phase 4·NCT07228221·20 enrolled
Topical Insulin for Glaucoma
Recruiting·SStanford University·Phase 1·NCT05206877·52 enrolled
Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
Recruiting·UUniversity College, London·Phase 3·NCT05405868·496 enrolled
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Recruiting·IInsight Eyecare Specialties, Inc. dba Vision Source Eyecare,·Phase 4·NCT07209410·35 enrolled
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
Recruiting·IIVIEW Therapeutics Inc.·Phase 1/2·NCT06921317·12 enrolled
Optic Nerve Head Strain in Non-glaucoma Subjects
Recruiting·JJohns Hopkins University·Phase 1·NCT07425535·30 enrolled
The Vizio Clinical Study: A Prospective, Multicenter, Feasibility Clinical Study to Evaluate the Safety and Efficacy of the Vizio Aqueous Microshunt for the Treatment of Refractory Glaucoma
Recruiting·OOcumedex·Preclinical·NCT06591117·50 enrolled
Ocular Blood Flow Imaging for Glaucoma Assessment
Recruiting·UUniversity of Maryland, Baltimore·Preclinical·NCT05726058·150 enrolled
Clinical Testing Pilot of the World Sight Foundation Field Machine (WSFFM) in Glaucoma Patients - Comparison With Humphrey Visual Field Analyser
Recruiting·BBuckinghamshire Healthcare NHS Trust·Preclinical·NCT07674069·100 enrolled
Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
Recruiting·NNantes University Hospital·N/A·NCT06274593·50 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)